Drug Trial Radar · NCT06577376
A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
Last checked: Nov 19, 2026Latest source record: Sep 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
252
Planned (sponsor's estimate)
Start
Aug 26, 2024
Primary completion
Aug 26, 2026
Study completion Aug 26, 2027
Sponsor
- Lead sponsor
- Shanghai Runshi Pharmaceutical Technology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is divided into two parts: Cohort 1 and Cohort 2. Cohort 1 includes the dose escalation phase of DP303c combined with simmitinib, as well as the randomized controlled trial (RCT) phase of DP303c combined with simmitinib; Cohort 2 includes dose escalation/dose extension of DP303c combined with irinotecan liposomes, as well as RCT stage of DP303c combined with irinotecan liposomes.
Conditions
- Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
- Expressing Human Epidermal Growth Factor Receptor-2 (HER-2)
- Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past
Interventions
DP303cDrug
DP303c is an antibody conjugate drug (ADC), composed of one anti-HER2 monoclonal antibody coupled to one MMAE via an enzyme specific linker
Simmitinib tabletsDrug
A novel small molecule inhibitor targeting fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR2, KDR), and colony-stimulating factor 1 receptor (CSF-1R)
Irinotecan liposomesDrug
A chemotherapy
Paclitaxel or docetaxel or irinotecanDrug
Paclitaxel or docetaxel or irinotecan is used as a control.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicity(DLT) occurrence and incidenceTime frame: Up to approximately 36 months after the first participant is enrolled
- Adverse events (AE) occurrence and incidenceTime frame: Up to approximately 36 months after the first participant is enrolled
- Objective response rate (ORR) per RECIST 1.1Time frame: Up to approximately 36 months after the first participant is enrolled
- Serious adverse events (SAE) occurrence and incidenceTime frame: Up to approximately 36 months after the first participant is enrolled
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.